New drug targets 'Undruggable' cancer mutation in first human trial
Disease control
Ongoing
This is a first-in-human study to check the safety and early effectiveness of a new drug, QTX3544, for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The trial will test QTX3544 given alone or combined with an existing cancer drug, cetuxim…
Phase: PHASE1 • Sponsor: Quanta Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC